Program
dazucorilant
Also written as “Dazucorilant”, “Dazucorilant 300 mg” and “Dazucorilant 150 mg”.
Its studies are mostly in Amyotrophic Lateral Sclerosis, led by Corcept Therapeutics.
Furthest: phase 2, since Jun 2, 20226 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Corcept Therapeutics | 61 open or running | phase 2since Jun 2, 2022 | Jan 29, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 29, 2020First study: phase 1 study in Healthy AdultsFirst studyNCT04249323 · 110 enrolled · United Kingdom
- Jul 27, 20212 phase 1 studiesNCT04990310, NCT04994743
- Jun 2, 2022Phase 2 study in Amyotrophic Lateral SclerosisNCT05407324 · 279 enrolled · United States, Belgium, Canada and more
- Jul 3, 2024Phase 1 study in Healthy AdultsNCT06495944 · 21 enrolled · United States
- Apr 8, 2025Phase 1 study in Hepatic ImpairmentNCT06928779 · 19 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06928779Hepatic Impairment · United States | 1 | Completed | Dec 9, 2024 | 19 |
| NCT06495944Healthy Adults · United States | 1 | Completed | Aug 2, 2024 | 21 |
| NCT05407324Amyotrophic Lateral Sclerosis · United States, Belgium, Canada and more | 2 | Active, not recruiting | Oct 2026 | 279 |
| NCT04994743Healthy Adults · Netherlands | 1 | Completed | Sep 30, 2021 | 16 |
| NCT04990310Healthy · United Kingdom | 1 | Completed | Sep 20, 2021 | 6 |
| NCT04249323Healthy Adults · United Kingdom | 1 | Completed | Oct 15, 2020 | 110 |
How it is read
Names in the registry
- “Dazucorilant”, 3 entries
- “Dazucorilant 300 mg”, 1 entry
- “Dazucorilant 150 mg”, 1 entry
- “CORT113176 Lipid Capsule Formulation”, 1 entry
- “[14C]-CORT113176”, 1 entry
Conditions, from the studies’ own filings
- Amyotrophic Lateral Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.